BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

13441

524824

BALPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BAL PHARMA LTD. performance

Today’s low

Today’s high

₹ 102.51 ₹ 104.50
₹ 103.48

52 week low

52 week high

₹ 78.06 ₹ 157.98
₹ 103.48

Open Price

₹ 104.00

Prev. Close

₹ 103.59

Volume (Shares)

6410.00

Total traded value

₹ 6.63

Upper Circuit

₹ 124.30

Lower Circuit

₹ 82.87

info

BAL PHARMA LTD. Share Price Update

As of the latest trading session, BAL PHARMA LTD. share price is currently at ₹ 103.28, which is down by ₹ -0.30 from its previous closing. Today, the stock has fluctuated between ₹ 102.51 and ₹ 104.50. Over the past year, BAL PHARMA LTD. has achieved a return of -13.70 %. In the last month alone, the return has been 5.68 %. Read More...

Investment Returns

Over 1 Month 5.68% Over 3 Months -15.33% Over 6 Months -15.37% Over 1 Year -13.70%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BAL PHARMA LTD. fundamentals


  • Market cap (Cr)

    164.70

  • P/E Ratio (TTM)

    21.03

  • Beta

    0.75

  • Book Value / share

    70.66

  • Return on equity

    10.19%

  • EPS (TTM)

    4.90

  • Dividend yield

    1.16%

  • Net profit/quarter (Cr)

    5.61

info icon alternate text
  • Market cap (Cr)

    164.10

  • P/E Ratio (TTM)

    21.03

  • Beta

    0.69

  • Book Value / share

    70.66

  • Return on equity

    10.19%

  • EPS (TTM)

    4.90

  • Dividend yield

    1.16%

  • Net profit/quarter (Cr)

    5.61

info icon alternate text

BAL PHARMA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 81.78
Operating Expense 79.96
Net Profit 5.61
Net Profit Margin (%) 6.85
Earnings Per Share (EPS) 3.51
EBITDA 8.82
Effective Tax Rate (%) -99.28
Particulars DEC 2024 (Values in Cr)
Revenue 72.89
Operating Expense 72.64
Net Profit 0.69
Net Profit Margin (%) 0.94
Earnings Per Share (EPS) 0.73
EBITDA 8.44
Effective Tax Rate (%) 6.75
Particulars SEP 2024 (Values in Cr)
Revenue 74.70
Operating Expense 73.52
Net Profit 1.20
Net Profit Margin (%) 1.60
Earnings Per Share (EPS) 0.76
EBITDA 7.81
Effective Tax Rate (%) 21.05
Particulars JUN 2024 (Values in Cr)
Revenue 73.13
Operating Expense 71.83
Net Profit 1.75
Net Profit Margin (%) 2.39
Earnings Per Share (EPS) 1.11
EBITDA 7.90
Effective Tax Rate (%) 17.06
Particulars MAR 2024 (Values in Cr)
Revenue 94.58
Operating Expense 90.88
Net Profit 5.34
Net Profit Margin (%) 5.64
Earnings Per Share (EPS) 4.16
EBITDA 11.03
Effective Tax Rate (%) 3.78
Particulars MAR 2025 (Values in Cr)
Revenue 302.50
Operating Expense 298.92
Net Profit 7.80
Net Profit Margin (%) 2.57
Earnings Per Share (EPS) 4.89
EBITDA 32.23
Effective Tax Rate (%) -36.12
Particulars MAR 2024 (Values in Cr)
Revenue 338.54
Operating Expense 331.52
Net Profit 7.73
Net Profit Margin (%) 2.28
Earnings Per Share (EPS) 6.72
EBITDA 33.83
Effective Tax Rate (%) 17.06
Particulars MAR 2023 (Values in Cr)
Revenue 303.10
Operating Expense 296.73
Net Profit 6.13
Net Profit Margin (%) 2.02
Earnings Per Share (EPS) 3.90
EBITDA 28.49
Effective Tax Rate (%) 28.30
Particulars MAR 2022 (Values in Cr)
Revenue 280.37
Operating Expense 274.79
Net Profit 8.58
Net Profit Margin (%) 3.06
Earnings Per Share (EPS) 5.79
EBITDA 29.70
Effective Tax Rate (%) 28.85
Particulars MAR 2021 (Values in Cr)
Revenue 249.31
Operating Expense 242.21
Net Profit 9.10
Net Profit Margin (%) 3.65
Earnings Per Share (EPS) 6.41
EBITDA 29.02
Effective Tax Rate (%) 7.14
Particulars MAR 2024 (Values in Cr)
Book Value / Share 43.42
ROE % 11.20
ROCE % 11.74
Total Debt to Total Equity 2.03
EBITDA Margin 10.19
Particulars MAR 2023 (Values in Cr)
Book Value / Share 40.66
ROE % 4.28
ROCE % 9.16
Total Debt to Total Equity 1.92
EBITDA Margin 8.61
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.92
ROE % 9.04
ROCE % 11.02
Total Debt to Total Equity 1.90
EBITDA Margin 9.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 35.52
ROE % 8.89
ROCE % 9.32
Total Debt to Total Equity 2.16
EBITDA Margin 10.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 36.99
ROE % -21.65
ROCE % -0.43
Total Debt to Total Equity 2.03
EBITDA Margin 4.02
Particulars MAR 2024 (Values in Cr)
Book Value / Share 66.81
ROE % 10.19
ROCE % 11.63
Total Debt to Total Equity 1.28
EBITDA Margin 10.63
Particulars MAR 2023 (Values in Cr)
Book Value / Share 61.21
ROE % 6.69
ROCE % 10.08
Total Debt to Total Equity 1.22
EBITDA Margin 9.44
Particulars MAR 2022 (Values in Cr)
Book Value / Share 58.28
ROE % 9.36
ROCE % 11.20
Total Debt to Total Equity 1.21
EBITDA Margin 10.22
Particulars MAR 2021 (Values in Cr)
Book Value / Share 52.88
ROE % 12.53
ROCE % 12.18
Total Debt to Total Equity 1.40
EBITDA Margin 11.75
Particulars MAR 2020 (Values in Cr)
Book Value / Share 46.53
ROE % -12.46
ROCE % 2.03
Total Debt to Total Equity 1.43
EBITDA Margin 6.23
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.29
Total Assets 319.52
Total Liabilities 319.52
Total Equity 69.26
Share Outstanding 15804372
Price to Book Ratio 1.37
Return on Assets (%) 2.31
Return on Capital (%) 3.54
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.61
Total Assets 313.17
Total Liabilities 313.17
Total Equity 63.70
Share Outstanding 15689872
Price to Book Ratio 1.09
Return on Assets (%) 0.82
Return on Capital (%) 1.32
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.39
Total Assets 260.53
Total Liabilities 260.53
Total Equity 58.49
Share Outstanding 14823720
Price to Book Ratio 1.85
Return on Assets (%) 2.15
Return on Capital (%) 3.59
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.85
Total Assets 240.08
Total Liabilities 240.08
Total Equity 53.35
Share Outstanding 14823720
Price to Book Ratio 1.02
Return on Assets (%) 1.97
Return on Capital (%) 3
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.13
Total Assets 238.38
Total Liabilities 238.38
Total Equity 45.33
Share Outstanding 14172372
Price to Book Ratio 0.70
Return on Assets (%) -5.12
Return on Capital (%) -7.73
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.13
Total Assets 361.30
Total Liabilities 361.30
Total Equity 105.58
Share Outstanding 15804372
Price to Book Ratio 1.37
Return on Assets (%) 2.84
Return on Capital (%) 4.29
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.35
Total Assets 347.70
Total Liabilities 347.70
Total Equity 96.03
Share Outstanding 15689872
Price to Book Ratio 1.09
Return on Assets (%) 1.76
Return on Capital (%) 2.77
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.09
Total Assets 289.76
Total Liabilities 289.76
Total Equity 87.32
Share Outstanding 14822372
Price to Book Ratio 1.85
Return on Assets (%) 2.96
Return on Capital (%) 4.63
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.71
Total Assets 261.53
Total Liabilities 261.53
Total Equity 79.31
Share Outstanding 14822372
Price to Book Ratio 1.02
Return on Assets (%) 3.47
Return on Capital (%) 4.96
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.94
Total Assets 239.31
Total Liabilities 239.31
Total Equity 65.94
Share Outstanding 14172372
Price to Book Ratio 0.70
Return on Assets (%) -3.71
Return on Capital (%) -5.57
Particulars MAR 2024 (Values in Cr)
Net Income 9.04
Cash from Operations 27.34
Cash from Investing -18.89
Cash from Financing -1.20
Net change in Cash 2.70
Free Cash Flow 38.31
Particulars MAR 2023 (Values in Cr)
Net Income 4.74
Cash from Operations -1.03
Cash from Investing -22.18
Cash from Financing 24.09
Net change in Cash 0.37
Free Cash Flow 13.61
Particulars MAR 2022 (Values in Cr)
Net Income 9.18
Cash from Operations 27.99
Cash from Investing -9.48
Cash from Financing -17.22
Net change in Cash 0.08
Free Cash Flow 36.46
Particulars MAR 2021 (Values in Cr)
Net Income 4.10
Cash from Operations 22.44
Cash from Investing -5.53
Cash from Financing -16.63
Net change in Cash 0.16
Free Cash Flow 22.44
Particulars MAR 2020 (Values in Cr)
Net Income -13.52
Cash from Operations 23.41
Cash from Investing -4.70
Cash from Financing -19.97
Net change in Cash -1.43
Free Cash Flow 23.41
Particulars MAR 2024 (Values in Cr)
Net Income 12.10
Cash from Operations 33.49
Cash from Investing -18.42
Cash from Financing -7.71
Net change in Cash 2.80
Free Cash Flow 43.99
Particulars MAR 2023 (Values in Cr)
Net Income 8.54
Cash from Operations 5.87
Cash from Investing -22.08
Cash from Financing 17.12
Net change in Cash 0.41
Free Cash Flow 20.41
Particulars MAR 2022 (Values in Cr)
Net Income 12.05
Cash from Operations 31.68
Cash from Investing -13.43
Cash from Financing -17.21
Net change in Cash -0.07
Free Cash Flow 39.25
Particulars MAR 2021 (Values in Cr)
Net Income 9.79
Cash from Operations 10.34
Cash from Investing -6.65
Cash from Financing -3.36
Net change in Cash 0.21
Free Cash Flow 13.15
Particulars MAR 2020 (Values in Cr)
Net Income -9.07
Cash from Operations 21.88
Cash from Investing -3.15
Cash from Financing -19.93
Net change in Cash -1.37
Free Cash Flow 25.48
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 27.82 1.99 279.33 34.11 / 77.70
BLISS GVS PHARMA LTD 156.00 19.50 1.56 1643.78 103.10 / 184.95
CIPLA LTD 1513.50 23.76 3.91 122246.58 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 328.70 12.58 2.66 967.40 170.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 36.45 5.76 279.33 34.11 / 77.70
AMRUTAJAN HEALTH LTD 712.85 40.55 6.30 2060.89 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9090.60 129.83 29.50 22726.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD 156.00 23.82 1.55 1643.78 103.10 / 184.95

BAL PHARMA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
103.48 -0.10 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 102.60
  • 26 Days 101.00
  • 10 Days 101.80
  • 50 Days 100.60
  • 12 Days 101.70
  • 100 Days 102.20
  • 20 Days 101.20
  • 200 Days 106.10
103.00 PIVOT

First Support

101.61

First Resistance

104.98

Second Support

99.63

Second Resistance

106.37

Third Support

98.24

Third Resistance

108.35

RSI

58.82

ADX

20.38

MACD

0.64

Williams % R

-28.31

Commodity Channel Index (CCI)

68.65

Date

2025-07-04

Week

9534.00

Same Day

3694.00

Month

15196.00

1 Year

0.76

3 Year

0.65

Over 1 Month

5.68%

down

Over 1 Year

-13.70%

down

Over 3 Months

-15.33%

down

Over 3 Years

3.01%

down

Over 6 Months

-15.37%

down

Over 5 Years

19.42%

down

BAL PHARMA LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
49.0%
Promoter Holdings
50.85%
FII
0.13%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shailesh Siroya 2745459.0 (17.24%) Shareholding of Promoter and Promoter Group
Micro Labs Limited 2011736.0 (12.64%) Shareholding of Promoter and Promoter Group
Anita Siroya 1049220.0 (6.59%) Shareholding of Promoter and Promoter Group
Prakash Chandra Jain 581270.0 (3.65%) Public Shareholding
Ram Keshav Murthy 527600.0 (3.31%) Public Shareholding
Anand Surana 525686.0 (3.3%) Shareholding of Promoter and Promoter Group
Chandraprakash Dheerajmal Siroya 486420.0 (3.06%) Shareholding of Promoter and Promoter Group
Dilip Surana 474994.0 (2.98%) Shareholding of Promoter and Promoter Group
Naresh D.p 300000.0 (1.88%) Public Shareholding
Shreya Mardia 300000.0 (1.88%) Public Shareholding
Asha Tapidas Dhodia 293247.0 (1.84%) Public Shareholding
Archana Surana 284996.0 (1.79%) Shareholding of Promoter and Promoter Group
Gautam Chand Mehta 189966.0 (1.19%) Public Shareholding
Monica Surana 179909.0 (1.13%) Shareholding of Promoter and Promoter Group
Dilip Surana (huf) 169995.0 (1.07%) Shareholding of Promoter and Promoter Group
Anita Chandraprakash Siroya 122687.0 (0.77%) Shareholding of Promoter and Promoter Group
Jivi Dheerajmal Siroya 46080.0 (0.29%) Shareholding of Promoter and Promoter Group
Shrenik D Siroya 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

BAL PHARMA LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 1.0 Final 19 Sep 2023 Equity shares
13 Sep 2022 1.0 Final 15 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 18 Sep 2021 Equity shares
17 Sep 2019 1.0 Final 19 Sep 2019 Equity shares
14 Sep 2018 1.0 Final 18 Sep 2018 Equity shares
14 Sep 2017 1.0 Final 18 Sep 2017 Equity shares
15 Sep 2016 1.0 Final 18 Sep 2016 Equity shares
15 Sep 2015 1.0 Final 18 Sep 2015 Equity shares
12 Sep 2014 1.0 Final 16 Sep 2014 Equity shares
12 Sep 2013 0.75 Final 16 Sep 2013 Equity shares
17 Sep 2009 0.75 Final 22 Sep 2009 Equity shares
09 Sep 2008 1.0 Final 11 Sep 2008 Equity shares
07 Sep 2007 0.75 Final 11 Sep 2007 Equity shares
09 Sep 2005 0.0 Final 13 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 1.0 Final 19 Sep 2023 Equity shares
13 Sep 2022 1.0 Final 15 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 18 Sep 2021 Equity shares
17 Sep 2019 1.0 Final 19 Sep 2019 Equity shares
14 Sep 2018 1.0 Final 18 Sep 2018 Equity shares
14 Sep 2017 1.0 Final 18 Sep 2017 Equity shares
15 Sep 2016 1.0 Final 18 Sep 2016 Equity shares
15 Sep 2015 1.0 Final 18 Sep 2015 Equity shares
12 Sep 2014 1.0 Final 16 Sep 2014 Equity shares
12 Sep 2013 0.75 Final 16 Sep 2013 Equity shares
17 Sep 2009 0.75 Final 22 Sep 2009 Equity shares
09 Sep 2008 1.0 Final 11 Sep 2008 Equity shares
07 Sep 2007 0.75 Final 11 Sep 2007 Equity shares
09 Sep 2005 0.0 Final 13 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

BAL PHARMA LTD. Share Price

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.

BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.

The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named 'SERVETUS' has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.

The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores.

In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug's
manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.

Parent organization Indian Private
NSE symbol BALPHARMA
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bal Pharma Ltd?

Answer Field

Bal Pharma Ltd share price is for NSE ₹ 103.28 & for BSE ₹ 103.05 as on Jul 04 2025 03:29 PM.

What is the Market Cap of Bal Pharma Ltd Share?

Answer Field

The market cap of Bal Pharma Ltd for NSE ₹ 163.22 & for BSE ₹ 162.86 as on Jul 04 2025 03:29 PM.

What is the 52 Week High and Low of Bal Pharma Ltd?

Answer Field

The 52 Week High and Low of Bal Pharma Ltd for NSE is ₹ 157.98 and ₹ 78.06 and for BSE is ₹ 157.90 and ₹ 76.30.

What is 1 year return for Bal Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -13.70%.

What is the P/E Ratio of Bal Pharma Ltd Share?

Answer Field

As on Jul 04 2025 03:29 PM the price-to-earnings (PE) ratio for Bal Pharma Ltd share is 21.03.

What is the PB ratio of Bal Pharma Ltd Share?

Answer Field

As on Jul 04 2025 03:29 PM, the price-to-book (PB) ratio for Bal Pharma Ltd share is 70.66.

How to Buy Bal Pharma Ltd Share?

Answer Field

You can trade in Bal Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bal Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Bal Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bal Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|